Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Next Previous
Trial Profile

A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms BE AGILE; BE-AGILE
  • Sponsors UCB Biopharma

    • Most Recent Events

    • 15 Nov 2023 5-yr results of Bimekizumab in BE AGILE and its OLE, presented at the ACR Convergence 2023
    • 15 Nov 2023 Results of pooled analysis of studies (BE MOBILE 1, BE MOBILE 2, BE MOVING,BE MOBILE 1,BE MOBILE 2,BE AGILE, BE AGILE 2, assessing incidence of uveitis following inhibition of IL-7A in addition to IL-7F with bimekizumab in patients with Axial Spondyloarthritis were presented at the ACR Convergence 2023.
    • 10 Nov 2023 According to an UCB Media Release, data from the study were presented at the American College of Rheumatology (ACR) Convergence 2023 in San Diego, November 10-15.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top